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A B S T R A C T
Background
Asymmetric dimethylarginine (ADMA) is a naturally occurring inhibitor of nitric oxide
synthesis that accumulates in a wide range of diseases associated with endothelial dysfunction
and enhanced atherosclerosis. Clinical studies implicate plasma ADMA as a major novel
cardiovascular risk factor, but the mechanisms by which low concentrations of ADMA produce
adverse effects on the cardiovascular system are unclear.
Methods and Findings
We treated human coronary artery endothelial cells with pathophysiological concentrations
of ADMA and assessed the effects on gene expression using U133A GeneChips (Affymetrix).
Changes in several genes, including bone morphogenetic protein 2 inducible kinase (BMP2K),
SMA-related protein 5 (Smad5), bone morphogenetic protein receptor 1A, and protein arginine
methyltransferase 3 (PRMT3; also known as HRMT1L3), were confirmed by Northern blotting,
quantitative PCR, and in some instances Western blotting analysis to detect changes in protein
expression. To determine whether these changes also occurred in vivo, tissue from gene
deletion mice with raised ADMA levels was examined. More than 50 genes were significantly
altered in endothelial cells after treatment with pathophysiological concentrations of ADMA (2
lM). We detected specific patterns of changes that identify pathways involved in processes
relevant to cardiovascular risk and pulmonary hypertension. Changes in BMP2K and PRMT3
were confirmed at mRNA and protein levels, in vitro and in vivo.
Conclusion
Pathophysiological concentrations of ADMA are sufficient to elicit significant changes in
coronary artery endothelial cell gene expression. Changes in bone morphogenetic protein
signalling, and in enzymes involved in arginine methylation, may be particularly relevant to
understanding the pathophysiological significance of raised ADMA levels. This study identifies
the mechanisms by which increased ADMA may contribute to common cardiovascular diseases
and thereby indicates possible targets for therapies.
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Introduction
Asymmetric dimethylarginine (ADMA) is an endogenous
inhibitor of all nitric oxide synthase (NOS) isoforms [1]. It is
synthesised by the action of protein arginine methyltrans-
ferases (PRMTs), and following proteolysis, free ADMA is
released into the cell cytosol and thence into plasma.
Circulating concentrations of ADMA are increased in
patients with renal failure [1], pulmonary hypertension, heart
failure, hypercholesterolemia or a wide range of other
cardiovascular risk factors [2–6]. In patients with end-stage
renal failure, the plasma levels of ADMA predict mortality
and cardiovascular outcome [7], and in a cohort of otherwise
healthy Finnish men, those with the highest levels of ADMA
had an increased risk of acute coronary events [8]. Increased
circulating ADMA in pregnant women predicts an increased
risk of pre-eclampsia and intrauterine growth retardation [9].
Despite these clinical observations and the increasing
excitement surrounding the use of ADMA as a risk marker
for vascular disease [3,7], it is still not clear whether ADMA
has a causal role in pathophysiology. It has been argued that
the concentration of ADMA in plasma is too low to be an
effective inhibitor of NOS, and that the usual concentrations
of arginine in cells should overcome any inhibitory effects of
ADMA on NOS [10]. In order to determine how ADMA might
exert effects on endothelial cells and produce pathology, we
assessed the effects of ADMA on gene expression in human
coronary endothelial cells.
Methods
Cell Culture
Human coronary artery endothelial cells (HCAEC) were
purchased from Promocell and grown according to the
manufacturer’s instructions. HCAEC in 75-cm2 ﬂasks at
70% conﬂuency (passage 3 or 4) were treated for 24 h with
complete media supplemented with asymmetric dimethylar-
ginine (NGNG-dimethyl-L-arginine; ADMA; 0, 2, or 100 lM;
Figure 1. Flow Diagram Summarising the Methods Used in This Manuscript
DOI: 10.1371/journal.pmed.0020264.g001
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Merck Biosciences, United Kingdom). This was repeated on
three separate occasions with different batches of cells. RNA
from each study was used as described below for GeneChip
(Affymetrix, Santa Clara, California, United States) analysis.
Our strategy for the GeneChip and subsequent analysis is
outlined in Figure 1.
GeneChip Experiments
ADMA-treated HCAEC from T75 ﬂasks were harvested in
7.5 ml of TRIzol (Invitrogen, Carlsbad, California, United
States), and total RNA was extracted; cDNA and subsequent
cRNA synthesis were prepared as previously described [11].
The quality of the biotin-labelled cRNA transcripts was
determined using a Bioanalyser 2100 (Agilent Technologies,
Palo Alto, California, United States). Puriﬁed cRNA (15 lg)
was fragmented and hybridised to human U133A GeneChips
according to Affymetrix standard protocols (http://www.
affymetrix.com). Labelled GeneChips were scanned, using a
confocal argon ion laser (Agilent Technologies).
GeneChip Data Analysis
The U133A GeneChip contains oligonucleotides derived
from approximately 22,000 human transcripts and includes
control bacterial genes bioB, bioC, bioD, and cre. GeneChip data
ﬁles scaled to 100 and normalised to the median prior to
analysis with GeneSpring 7.2 software (Agilent; Figure 1).
Genes were excluded if the signal strength did not signiﬁ-
cantly exceed background values and if expression did not
reach a threshold value for reliable detection (based on the
relaxed Affymetrix MAS 5.0 probability of detection (p  0.1;
[12]) in each of the three separate studies. Finally, genes were
excluded if the level of expression did not vary by more than
1.7-fold between ADMA-treated (2 or 100 lM) compared with
untreated control HCAEC. The remaining genes were
subjected to nonparametric Welch t-tests and are reported
with their respective fold changes and p-values. The data have
been submitted in a MIAME-compliant format to ArrayEx-
press at EBI (http://www.ebi.ac.uk/arrayexpress/).
Determination of ADMA Levels
HCAEC cells were grown in 75-cm2 ﬂasks as described
above for 24 h. Methylated arginines in the conditioned
medium were quantitated by HPLC as previously described
[1,13].
Cell Growth Assay
Cells were seeded into a 96-well microtitre plate at a
density of 500 cells per well and grown in complete EC
medium in the presence of 0, 2, or 100 lM ADMA. Cell
growth was assayed (in triplicate) over a 4-d period using the
CellTiter 96 Aqueous One Solution Cell Proliferation Assay
(Promega, Madison, Wisconsin, United States).
Confirmation of Gene Changes
For genes of interest selected on the initial GeneChip
analysis, further experiments were undertaken, with different
batches of cells, to verify changes detected by global
expression proﬁling and using different approaches to assess
mRNA or protein.
RT-PCR
For RT-PCR cDNA was synthesised from the total RNA
(approximately 1 lg) using Ready-To-Go You-Prime First-
Strand Beads (Amersham Biosciences, Little Chalfont, United
Kingdom) and supplemented with the 39 gene-speciﬁc
primers with b-actin as a control. RT-PCR used the primer
sequences (Table 1) with b-actin as a control.
The PCR products were separated in 1% agarose gel, and
the intensity of the bands was measured; each sample was
corrected for b-actin. PCR products used for Northern
blotting were excised and puriﬁed from agarose gel using
Qiaex II (Qiagen, Valencia, California, United States).
Quantitative-PCR
Quantitative PCR (Q-PCR) was carried out using a Light-
Cycler (Roche, Alameda, California, United States) and
LightCycler software version 3, LightCycler run 4.24. All
reagents required for PCR (excluding cDNA and primers)
were included in the LightCycler FastStart DNA Master SYBR
Green 1 kit (Roche). Reverse transcription was performed as
described above for RT-PCR. The PCR cycle settings were 95
8C for 5 min, followed by 45 cycles of 95 8C for 5 s, 58 8C for 10
s (60 8C for b-actin), 72 8C for 40 s, and 77 8C (82 8C for b-actin),
where ﬂuorescence was measured at the end of each cycle and
is gene-speciﬁc. Standard curves were constructed for PRMT3
as described by the manufacturer’s instructions and com-
pared to the reference gene b-actin.
Northern Blotting
HCAEC were grown to 70% conﬂuency in 6-well plates and
treated with 0, 2, and 100 lM ADMA, 100 lM L-N5-(1-
Iminoethyl)ornithine (L-NIO), or 100 lM symmetric dime-
thylarginine (SDMA) for 24 h; total RNA was extracted using
Table 1. Primer Sequences for Q-PCR and RT-PCR
Probe 39 Oligo 59 Oligo
BMP2K TGTTGCTGCTGTGTTGCATGA TATTGGGTCAGGGACCTCCTCA
SMAD5 CACCTCTCCACCAACATAGTAC ATAATTCCCAGCCTATGGATAC
BMPR1A TAGTTCGCTGAACCAATAAAGG GTCAGAAAATGGAGTAACCTTA
PRMT3a CTTCGCCCCAGCTTTA TACGGGCATTATGGGAT
b-actina AAATCCTGAGTCAAGCCAAAAA CCACGAAACTACCTTCAACTCC
mBMP2K CTTCAGATCCCGGTGGATTA ACACACCCGACCTCAACATT
mPRMT3 GACCCTGTTGTTGGCAATTCT CTTCCTGTGGAAAAGGTGGA
mb-actin CATGATCTGGGTCATCTTTTCA CATGATCTGGGTCATCTTTTCA
aPrimers were designed for use on the LightCycler (Roche).
DOI: 10.1371/journal.pmed.0020264.t001
Table 2. Oligonucleotide Sequences for 59-End-Labelling
Northern Blotting Experiments
Gene 59 Oligo
RpS11 AATAGCCTCCTTGGGTGTCTTGAA
Calreticulin AGAGCAGATGAAATCTCAGGCCTGT
SCAMP1 AGACAGGTGCATTTAGGGATTCAAG
RpL27 GGTGCCATCATCAATGTTCTTCACG
DOI: 10.1371/journal.pmed.0020264.t002
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TRIzol, and RNA was separated by gel electrophoresis and
blotted onto Hybond Nþ (Amersham Biosciences). The
ribosomal protein S11 (RpS11), ribosomal protein L-27
(RpL-27), Calreticulin, and secretory carrier membrane
protein 1 (SCAMP1) probes were generated by end-labelling
59 oligonucleotides (Table 2) using T4 polynucleotide kinase.
The PCR products from RT-PCR reaction for b-actin,
Smad5, bone morphogenetic protein receptor 1A (BMPR1A),
and murine b-actin (mb-actin); murine bone morphogenetic
protein 2 inducible kinase (mBMP2K), and murine protein
arginine methyltransferase 3 (mPRMT3) were puriﬁed and
labelled with Redivue deoxycytidine 59-[a-32P]-triphosphate
(Amersham Biosciences), using a random primed DNA
labelling kit (Roche).
Western Blotting
HCAEC were treated with either 0, 2, or 100 lM ADMA for
24 h in 6-well plates and harvested in lysis buffer as described
previously [11], the protein concentrations of the lysates were
determined by protein assay (Bio-Rad, Hercules, California,
United States), and cell lysates were resolved by 12% SDS
polyacryamide gel electrophoresis with equal amounts of
protein loaded into each lane. Anti-PRMT3 (Upstate Bio-
technology, Charlottesville, Virginia, United States) and Anti-
BMP2K (Orbigen, San Diego, California, United States) were
used with anti-rabbit secondary antibody coupled to horse-
radish peroxidase and detected with the ECLþ detection
system (Amersham Pharmacia, Piscataway, New Jersey, United
States). Densitometry of the bands was determined, and
results are shown as the mean densitometry, where n¼ 4 with
inset of a typical Western blot.
Pathway Mapping and Gene Ontology Analysis
In order to determine whether ADMA had affected
expression of genes in pathways related to the genes
identiﬁed on the initial analysis, lists of genes that were
changed more than 1.7-fold compared to control (irrespec-
tive of p-value) were examined using Gene Ontology
(Affymetrix) data mining for biological process (at level 3),
and Expression Analysis Systematic Explorer (EASE) bio-
logical theme analysis were conducted online at http://david.
niaid.nih.gov using DAVID [14]. DAVID-EASE [15] generates
an EASE score predicting the likelihood of genes mapping to
speciﬁc biological processes (determined by Gene Ontology
consortium) from a given list of changed genes, therefore
enabling global themes in gene expression following ADMA
treatment to be identiﬁed [15].
Dimethylarginine Dimethylaminohydrolase 1 Gene
Deletion Mice
ADMA is metabolised to citrulline and dimethylamine by
the action of dimethylarginine dimethylaminohydrolase
(DDAH). We have created knockout mice that lack DDAH1.
DDAH1 heterozygous knockout mice (details to be published
elsewhere) have approximately 2-fold higher plasma ADMA
levels compared to wild-type litter-mates and thus provide an
excellent model to test the effects of moderately raised
ADMA levels in vivo. Northern blotting was carried out using
RNA extracted from the brain, heart, and kidney of 12–14-
wk-old DDAH1 heterozygous knockout and wild-type litter-
mates with probes for mBMP2K and mPRMT3, and results are
expressed relative to mb-actin.
Statistical Analyses
Q-PCR, Northern blot, and Western blot densitometry data
for the treated HCAEC was analysed by one-way analysis of
variance (ANOVA) coupled to Bonferroni posttest, and the
Bonferroni posttest p-values are reported. The Northern
blots from the DDAH1 gene deletion mice were compared
with unpaired t-test and the p-values are reported.
Results
Changes in HCAEC Gene Expression in Response to ADMA
on U133A GeneChips
A total of 979 genes changed in expression between
ADMA-treated and control cells. Following the Welch t-test
with a cutoff of p , 0.05, 56 genes were identiﬁed as having
shown a statistically signiﬁcant change between the untreated
and 2-lM ADMA-treated cells, and 86 genes changed between
Figure 2. Endothelial Gene Expression Changes in Response to ADMA
(A) Changes in HCAEC gene expression in response to ADMA.
Hierarchical clustering of 131 genes significantly up- or downregulated
(p , 0.05, Welch t-test) by greater than 1.7-fold on the U133A GeneChips
in response to 2 lM ADMA (56 genes) or 100 lM ADMA (86 genes)
compared with untreated cells with 11 genes changing with both
concentrations of ADMA. Individual arrays are shown for each treatment
group with blue representing low expression, and red high expression
on the scale bar.
(B) Treatment of HCAEC with either 2 lM or 100 lM ADMA had no
significant effect on cell viability; n ¼ 6.
DOI: 10.1371/journal.pmed.0020264.g002
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the untreated and 100-lM ADMA greater than 1.7-fold; 11
genes showed statistically signiﬁcant changes at both concen-
trations of ADMA compared to untreated cells (Figure 2A;
Tables 3 and 4).
Effects of ADMA upon HCAEC Viability
Basal levels of ADMA and SDMA in HCAEC media were
0.17 6 0.01 lM and 0.22 6 0.02 lM, respectively, and
arginine levels exceeded 300 lM. No changes were observed
Table 3. Genes That Changed by More Than 1.7-Fold in 2 lM ADMA Treated HCAEC Compared to Untreated
Affymetrix ID Gene Title Gene Symbol Fold Change p-Value
213350_at aRibosomal protein S11 RpS11 8.065 0.0334
222364_at EST — 5.780 0.0168
213642_at aRibosomal protein L27 RpL27 4.386 0.0481
216859_x_at Golgi-specific brefeldin A resistance factor 1 GBF1 3.968 0.00706
212952_at aCalreticulin CALR 2.959 0.0472
204569_at Intestinal cell (MAK-like) kinase ICK 2.778 0.0491
203294_s_at Lectin, mannose-binding, 1 LMAN1 2.740 0.0433
210407_at Protein phosphatase 1A (formerly 2C), Magnesium-dependent, a-isoform PPM1A 2.674 0.036
205636_at SH3GL3 protein SH3GL3 2.404 0.00324
38290_at Regulator of G-protein signalling 14 RGS14 2.347 0.0235
208995_s_at Peptidyl-prolyl isomerase G (cyclophilin G) PPIG 2.315 0.0146
214716_at aBMP2 inducible kinase BMP2K 2.304 0.00128
213610_s_at Hypothetical protein MGC2610 MGC2610 2.299 0.0435
212209_at Thyroid hormone receptor associated protein 2 THRAP2 2.137 0.00562
214697_s_at ROD1 regulator of differentiation 1 (Schizosaccharomyces pombe) ROD1 2.132 0.02
213732_at Transcription factor 3 TCF3 2.119 0.0462
220112_at Hypothetical protein FLJ11795 FLJ11795 2.114 0.00623
219785_s_at F-box protein 31 FBXO31 2.079 0.00429
206928_at Zinc finger protein 124 (HZF-16) ZNF124 2.045 0.0274
221903_s_at Cylindromatosis (turban tumor syndrome) CYLD 2.024 0.0221
204662_at CP110 protein CP110 2.012 0.0165
212746_s_at KARP-1-binding protein KAB 1.980 0.0379
217540_at Transcribed locus, moderately similar to NP_055301.1 neuronal thread protein
AD7c-NTP (Homo sapiens)
— 1.946 0.00294
202364_at MAX interactor 1 MXI1 1.919 0.0268
204285_s_at Phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 1.916 0.0443
204010_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 1.905 0.046
202305_s_at Fasciculation and elongation protein zeta 2 (zygin II) FEZ2 1.862 0.028
201242_s_at ATPase, Naþ/Kþ transporting, b-1 polypeptide ATP1B1 1.845 0.0391
205416_s_at Ataxin 3 ATXN3 1.845 0.00666
218096_at 1-Acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransfer-
ase, e)
AGPAT5 1.838 0.00518
218930_s_at Hypothetical protein FLJ11273 FLJ11273 1.828 0.0495
214700_x_at RAP1 interacting factor homolog (yeast) RIF1 1.818 0.00974
215203_at Golgi autoantigen, golgin subfamily a, 4 GOLGA4 1.812 0.0128
202225_at V-crk sarcoma virus CT10 oncogene homolog (avian) CRK 1.805 0.0429
209318_x_at Pleiomorphic adenoma gene-like 1 PLAGL1 1.805 0.0433
202906_s_at Nijmegen breakage syndrome 1 (nibrin) NBS1 1.773 0.0492
215948_x_at Zinc finger protein 237 ZNF237 1.761 0.042
203202_at HIV-1 rev binding protein 2 HRB2 1.718 0.0449
215412_x_at Postmeiotic segregation increased 2-like 2 PMS2L2 1.706 0.0483
219021_at Ring finger protein 121 RNF121 0.588 0.0311
208704_x_at Amyloid b (A4) precursor-like protein 2 APLP2 0.582 0.0433
211590_x_at Thromboxane A2 receptor TBXA2R 0.579 0.0256
211385_x_at Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 SULT1A2 0.567 0.0237
217347_at EST — 0.563 0.0285
203873_at Possible global transcription activator SNF2L1 (SWI/SNF related matrix associated
actin-dependent regulator of chromatin subfamily A member 1).
SMARCA1 0.557 0.00757
222280_at EST — 0.551 0.0493
212699_at Secretory carrier membrane protein 5 SCAMP5 0.547 0.0427
213484_at Clone 23700 mRNA sequence — 0.543 0.0464
209998_at Phosphatidylinositol glycan, class O PIGO 0.499 0.0408
216421_at EST — 0.481 0.0194
209093_s_at Glucosidase, b; acid (includes glucosylceramidase) GBA 0.468 0.0117
207740_s_at Nucleoporin 62 kDa NUP62 0.428 0.0404
217142_at a subunit of the elongation factor-1 complex EEF1A 0.416 0.0266
212822_at HEG homolog HEG 0.412 0.0221
205777_at Dual specificity phosphatase 9 DUSP9 0.399 0.0055
208353_x_at Ankyrin 1, erythrocytic ANK1 0.205 0.0433
Fold changes and p-values of genes that changed by more than 1.7-fold in 2 lM ADMA treated HCAEC compared to untreated (p , 0.05 by Welch t-tests).
aGenes that were used for reanalysis in subsequent experiments.
DOI: 10.1371/journal.pmed.0020264.t003
PLoS Medicine | www.plosmedicine.org October 2005 | Volume 2 | Issue 10 | e2641035
Effects of ADMA upon Gene Expression
Table 4. Genes that Changed by More than 1.7-Fold in 100 lM ADMA-Treated HCAEC Compared to Untreated
Affymetrix ID Gene Title Gene Symbol Fold Change p-Value
222364_at EST — 11.06 0.00597
216859_x_at Golgi-specific brefeldin A resistance factor 1 GBF1 6.757 0.00045
204397_at Echinoderm microtubule-associated protein-like EMAP2 4.016 0.0201
212417_at aSecretory carrier membrane protein 1 SCAMP1 3.165 0.0307
213734_at Replication factor C (activator 1) 5, 36.5kDa RFC5 2.740 0.0259
214716_at aBMP2 inducible kinase BMP2K 2.695 0.00049
214078_at P21 (CDKN1A)-activated kinase 3 PAK3 2.500 0.0228
204142_at Enolase superfamily member 1 ENOSF1 2.488 0.00326
221765_at UDP-glucose ceramide glucosyltransferase UGCG 2.392 0.00264
215218_s_at Chromosome 19 open reading frame 14 C19orf14 2.336 0.0406
213732_at Transcription factor 3 TCF3 2.315 0.0141
213610_s_at Hypothetical protein MGC2610 MGC2610 2.309 0.0316
201424_s_at Cullin 4A CUL4A 2.278 0.0356
205636_at SH3GL3 protein SH3GL3 2.242 0.0395
217951_s_at PHD finger protein 3 PHF3 2.183 0.0174
220112_at Hypothetical protein FLJ11795 FLJ11795 2.128 0.00597
218297_at Chromosome 10 open reading frame 97 C10orf97 2.020 0.0376
217540_at Similar to NP_055301.1 neuronal thread protein AD7c-NTP — 2.020 0.00341
222335_at EST — 2.016 0.00276
212936_at Hypothetical protein DKFZp564D172 DKFZP564D172 1.949 0.0423
221649_s_at Peter Pan homolog (Drosophila) PPAN 1.898 0.0189
213320_at aProtein arginine N-methyltransferase 3 PRMT3 1.883 0.0339
212209_at Thyroid hormone receptor associated protein 2 THRAP2 1.883 0.0353
204237_at GULP, engulfment adaptor PTB domain containing 1 GULP1 1.880 0.0299
205191_at Retinitis pigmentosa 2 (X-linked recessive) RP2 1.880 0.0324
202663_at Wiskott-Aldrich syndrome protein interacting protein WASPIP 1.869 0.023
212855_at KIAA0276 protein KIAA0276 1.862 0.0192
220255_at Fanconi anemia, complementation group E FANCE 1.821 0.0339
205296_at Retinoblastoma-like 1 (p107) RBL1 1.792 0.0458
206102_at KIAA0186 gene product KIAA0186 1.786 0.047
200605_s_at Protein kinase, cAMP-dependent, regulatory, type I, a PRKAR1A 1.767 0.0491
218256_s_at Nucleoporin 54 kDa NUP54 1.754 0.0223
221222_s_at Hypothetical protein FLJ20519 FLJ20519 1.742 0.0163
221634_at Similar to RPL23AP7 protein MGC70863 1.736 0.0164
210148_at Homeodomain interacting protein kinase 3 HIPK3 1.727 0.037
202419_at Follicular lymphoma variant translocation 1 FVT1 1.721 0.0482
217542_at Carboxypeptidase M CPM 1.701 0.0122
209831_x_at Deoxyribonuclease II, lysosomal DNASE2 0.586 0.0186
200678_x_at Granulin GRN 0.579 0.0491
213829_x_at Tumor necrosis factor receptor superfamily, member 6b, decoy TNFRSF6B 0.577 0.0121
216041_x_at Granulin GRN 0.574 0.049
201434_at Tetratricopeptide repeat domain 1 TTC1 0.573 0.0294
203778_at Mannosidase, a A, lysosomal MANBA 0.566 0.0395
207239_s_at PCTAIRE protein kinase 1 PCTK1 0.565 0.0454
200913_at Protein phosphatase 1G (formerly 2C), PPM1G 0.564 0.0417
204473_s_at Zinc finger protein 592 ZNF592 0.564 0.00276
218797_s_at Sirtuin (silent mating type information regulation 2 homolog) 7 (Saccharomyces
cerevisiae)
SIRT7 0.561 0.0219
200643_at High-density lipoprotein binding protein (vigilin) HDLBP 0.560 0.0398
211941_s_at Prostatic binding protein PBP 0.556 0.0387
207559_s_at Zinc finger protein 261 ZNF261 0.552 0.0363
214035_x_at LOC399491 protein LOC399491 0.551 0.0113
216885_s_at WD repeat domain 42A WDR42A 0.551 0.0276
210589_s_at Glucosidase, b; acid (includes glucosylceramidase) GBA 0.550 0.014
203524_s_at Mercaptopyruvate sulfurtransferase MPST 0.550 0.0234
222217_s_at Solute carrier family 27 (fatty acid transporter), member 3 SLC27A3 0.548 0.045
209140_x_at Major histocompatibility complex, class I, B HLA-B 0.544 0.0451
205851_at Protein expressed in nonmetastatic cells 6, (nucleoside-diphosphate kinase) NME6 0.543 0.00934
211471_s_at RAB36, member RAS oncogene family RAB36 0.541 0.0235
221757_at HGFL gene MGC17330 0.539 0.016
215533_s_at Ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 0.538 0.0229
215178_x_at EST — 0.534 0.0116
204248_at Guanine nucleotide binding protein, a-11 (Gq class) GNA11 0.532 0.00662
212744_at Bardet-Biedl syndrome 4 BBS4 0.528 0.0119
208829_at TAP binding protein (tapasin) TAPBP 0.526 0.0292
209002_s_at KIAA1536 protein KIAA1536 0.522 0.0492
212040_at Trans-Golgi network protein 2 TGOLN2 0.519 0.0129
216283_s_at Poliovirus receptor PVR 0.519 0.0351
219931_s_at Kelch-like 12 (Drosophila) KLHL12 0.510 0.0291
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in HCAEC viability over 72 h in the presence of either 2 or
100 lM ADMA (Figure 2B).
Confirming Transcriptional Changes
To determine the reliability of changes identiﬁed by
GeneChip analysis, four genes were selected from those that
showed a statistically signiﬁcant change in either the 2 or 100
lM sample compared to control (Figure 3A). These were
SCAMP1, Calreticulin, (RpL27) and RpS11. In studies on a
different batch of HCAEC, Northern blotting conﬁrmed that
expression of these genes changed in response to ADMA
(Figure 3B).
In order to elucidate the mechanism of ADMA action,
HCAEC were also treated with the potent NOS inhibitor L-
NIO and SDMA, which is not a NOS inhibitor or DDAH
substrate, but is a naturally occurring methylarginine that
competes with arginine for the cationic amino acid trans-
porter [10,16]. Interestingly neither SDMA nor L-NIO elicited
signiﬁcant changes in the expression of RpS11, RpL27,
SCAMP1, or Calreticulin (Figure 3B).
Genes of Specific Interest Identified by GeneChip
Protein arginine methyltransferase. PRMT3 was selected as a
gene of interest, because of its involvement in ADMA
synthesis [17]. It changed 1.8-fold on the GeneChip untreated
versus 100 lM groups (p ¼ 0.0339; Figure 4A). In a separate
series of follow-up studies, HCAEC were treated with ADMA,
and PRMT3 gene expression was determined by Q-PCR.
PRMT3 mRNA levels increased following either low- or high-
dose ADMA treatment (Figure 4B untreated versus 2 lM, p ,
0.05; and untreated versus 100 lM, p , 0.01, n ¼ 6). PRMT3
protein expression also increased in response to ADMA
treatment (Figure 4C; untreated versus 2 lM; and untreated
versus 100 lM, p , 0.05, n ¼ 4). When HCAEC were treated
for 24 h with 2 lM SDMA or L-NIO, neither treatment
signiﬁcantly affected PRMT3 expression, whereas 100 lM
SDMA or L-NIO caused a small increase in PRMT3
expression (Figure 4B; n ¼ 6).
Bone morphogenetic protein 2 inducible kinase. We
identiﬁed that bone morphogenetic protein 2 inducible
kinase (BMP2K) changed on the GeneChip in response to
ADMA (2 lM and 100 lM ADMA increased expression by
2.304-fold [p ¼ 0.00128] and 2.695-fold [p , 0.001], respec-
tively; Figure 5A). In a separate series of experiments on a
different batch of HCAEC this increase in BMP2K expression
was conﬁrmed by RT-PCR (data not shown). Western blotting
also revealed that BMP2K protein levels were increased in
response to ADMA (Figure 5B); densitometry of these blots
indicated that there was a signiﬁcant increase (untreated
versus 2 lM, p , 0.05; and untreated versus 100 lM, p , 0.01,
n ¼ 4).
Identification of Genes Involved in Bone Morphogenetic
Protein Signalling
Having conﬁrmed changes in BMP2K expression, the total
list of 765 genes that changed greater than 1.7-fold in
response to 100 lM ADMA, was reexamined to identify
additional genes in the bone morphogenetic protein (BMP)
signalling pathway affected by ADMA. This analysis identiﬁed
Smad5 and BMPR1A (Figures 6 and 7). In a separate set of
studies Northern blotting conﬁrmed that mRNA was in-
creased in HCAEC after 24 h by either 2 or 100 lM ADMA for
Smad5 and BMPR1A (Smad5 untreated versus 2 lM and
untreated versus 100 lM; p , 0.05, n ¼ 4; Figure 6A; and
BMPR1A untreated versus 2 lM, p , 0.05 and untreated
versus 100 lM; p , 0.01, n ¼ 4; Figure 6B).
Identification of Global Changes in Gene Expression
All genes that changed by more than 1.7-fold (irrespective
of p-value) were entered into DAVID-EASE. EASE probability
scores were generated based upon the number of genes for
each biological process altered in response to ADMA (Tables
5 and 6), where these biological processes were deﬁned by
Table 4. Continued
Affymetrix ID Gene Title Gene Symbol Fold Change p-Value
202556_s_at Microspherule protein 1 MCRS1 0.502 0.00625
218216_x_at ADP-ribosylation-like factor 6 interacting protein 4 ARL6IP4 0.498 0.00504
211241_at Lipocortin 2 pseudogene LIP2 0.486 0.00553
202640_s_at RAN binding protein 3 RANBP3 0.484 0.0406
210378_s_at Sjogren’s syndrome nuclear autoantigen 1 SSNA1 0.480 0.0381
209093_s_at Glucosidase, b; acid (includes glucosylceramidase) GBA 0.467 0.0216
211160_x_at Actinin, a-1 ACTN1 0.463 0.018
217331_at SCC-112 protein SCC-112 0.463 0.0235
211911_x_at Major histocompatibility complex, class I, B HLA-B 0.444 0.0186
212822_at HEG homolog HEG 0.429 0.0275
208729_x_at Major histocompatibility complex, class I, B HLA-B 0.429 0.0301
210042_s_at Cathepsin Z CTSZ 0.401 0.0324
211230_s_at Phosphoinositide-3-kinase, catalytic, d polypeptide PIK3CD 0.396 0.0428
203273_s_at Tumor suppressor candidate 2 TUSC2 0.376 0.00316
218425_at TRIAD3 protein TRIAD3 0.360 0.0426
203143_s_at KIAA0040 gene product KIAA0040 0.354 0.0485
216180_s_at Synaptojanin 2 SYNJ2 0.346 0.0329
206031_s_at Ubiquitin-specific protease 5 (isopeptidase T) USP5 0.209 0.0292
Fold changes and p-values of genes that changed by more than 1.7-fold in 100 lM ADMA-treated HCAEC compared to untreated (p , 0.05 by Welch t-tests).
aGenes that were used for reanalysis in subsequent experiments.
DOI: 10.1371/journal.pmed.0020264.t004
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enriched Gene Ontology categories. These gene lists indi-
cated that ADMA affects genes involved in metabolism, RNA
splicing, transcription, and cell cycle regulation.
Gene Deletion Mice
To examine whether the effects observed in the cell culture
model were relevant to the in vivo situation, we determined
the expression level of certain genes in DDAH heterozygous
knockout mice that have 2-fold elevation in plasma ADMA
levels. Total RNA from DDAH1 heterozygous knockout was
probed for mBMP2K and mPRMT3 by Northern blotting and
corrected for mb-actin expression (Figure 8). Levels of
mBMP2K for brain, heart, and kidney, respectively, were 42
6 13.8% (p ¼ 0.047), 33.3 6 18.6% (p ¼ 0.038), 74.0 6
21.4% (p¼0.007), higher in DDAH1 heterozygous mice (n¼9)
compared with wild-type litter-mates (n¼ 5). A similar trend
was seen for the expression of mPRMT3 (data not shown).
Discussion
ADMA is an endogenous inhibitor of NOSs [1] and there is
an association between increased plasma levels of ADMA and
renal disease [1], pulmonary hypertension [5], preeclampsia
[9], and the progression of atherosclerosis [18,19]. Whilst the
concentration of ADMA in plasma of healthy adults varies
between 0.4 and 1 lM, it may increase to 1.45–4.0 lM with
certain diseases, and this increase is thought to be causally
involved in pathophysiology [1,6,7,9,20]. In the present study
we detected substantial changes in gene expression in
HCAEC after 24 h of exposure to concentrations of ADMA
similar to those reported in pathophysiological states.
Furthermore, we identiﬁed speciﬁc pathways of gene activa-
tion that give insight into the mechanisms by which ADMA
may contribute to disease. Surprisingly, some of these
changes appear to be independent of blockade of the L-
arginine:nitric oxide (NO) pathway.
Figure 3. Confirmation of Gene Expression Changed by GeneChip Analysis
(A) SCAMP1; Calreticulin, ribosomal protein L-27 (RpL27), and RpS11 signal-to-noise ratios derived from U133A GeneChip analysis where n¼ 3 (untreated
versus 100 lM: SCAMP1 changed 3.16-fold, p¼ 0.031; and untreated versus 2 lM: Calreticulin changed 2.96-fold, p¼ 0.047; RpS11, 8.065-fold, p¼ 0.033;
RpL27, 4.39-fold, p ¼ 0.048).
(B) SCAMP1; Calreticulin, RpL27, and RpS11mRNA levels are elevated by ADMA (2 and 100 lM; *p, 0.05 and **p, 0.01). SDMA (100 lM) and L-NIO (100
lM) did not elicit changes in gene expression as shown by Northern blotting, where mRNA was corrected for differences in b-actin mRNA expression.
DOI: 10.1371/journal.pmed.0020264.g003
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Low Concentrations of ADMA Alter Gene Expression
Acute administration of ADMA to healthy individuals
elicits a transient fall in heart rate and cardiac output and
increases blood pressure [2], but little is known of the
potential longer-term effects of raised ADMA. Zoccali et al.
reported that a 1-lM increment in ADMA above the upper
limits for healthy individuals was associated with increased
risk of cardiovascular mortality [7], and levels around 2 lM
seem to be associated with a number of diverse cardiovascular
pathologies [3,8]. In the current study, HCAEC were treated
with 2 or 100 lM ADMA. We repeated GeneChip analysis in
three separate studies and observed reproducible changes in
the expression of a subset of genes in response to low- and
high -dose ADMA. Because there is always a possibility of false
positives being identiﬁed on arrays, we tested the reprodu-
cibility of the GeneChip approach by selecting four genes
signiﬁcantly upregulated by ADMA treatment. In a separate
series of studies we conﬁrmed an increase in mRNA levels by
Northern blotting at both concentrations of ADMA. Thus it is
clear that pathophysiological concentrations of ADMA (2 lM)
affect endothelial cell gene expression even in the presence of
very high arginine concentrations (.300 lM). Endogenous
ADMA is metabolised by DDAH, and DDAH activity is the
major determinant of plasma ADMA concentrations [2]. To
determine whether the effects we saw in vitro would be
reproduced in vivo we examined DDAH1 knockout mice. At
least one of the gene changes we saw in vitro also occurs in
vivo since DDAH1 heterozygous knockout mice have in-
creased concentrations of ADMA in plasma and showed
upregulation of BMP2K in several tissues.
ADMA inhibits NOSs with an IC50 of about 5 lM, the
precise potency depending on the prevailing concentration
Figure 4. ADMA Alters PRMT3 Gene Expression and Protein Levels
(A) PRMT3 levels are changed by ADMA on U133A GeneChips where n¼
3 (untreated versus 100 lM: 1.88-fold increase, p¼ 0.034).
(B) PRMT3 mRNA is changed in HCAEC following 24-h exposure to ADMA
(2 and 100 lM) but not SDMA (100 lM) or L-NIO (100 lM), measured by
Q-PCR (*p , 0.05 and **p , 0.01, where n ¼ 8).
(C) PRMT3 protein levels are increased in HCAEC following 24-h
treatment with ADMA (2 and 100 lM) as determined by Western
blotting, using a commercially available PRMT3 antibody (Upstate
Biotechnology), where equal amounts of protein were loaded in each
lane. Densitometry of the PRMT3 was carried for each of the blots from
four separate experiments. ADMA (2 and 100 lM) treatment for 24 h
significantly increased the levels of PRMT3 (*p , 0.05). The inset blot is a
representative from four separate experiments.
DOI: 10.1371/journal.pmed.0020264.g004
Figure 5. ADMA Alters BMP2K Gene Expression and Protein Levels
(A) BMP2K is increased more than 2-fold in HCAEC following 24-h ADMA
treatment (2 lM and 100 lM ADMA increased expression by 2.304-fold
[p¼ 0.00128] and 2.695-fold [p , 0.001] respectively).
(B) BMP2K protein levels are increased in HCAEC following 24-h
treatment with ADMA (2 and 100 lM) as determined by Western
blotting, using a commercially available BMP2K antibody (Orbigen).
Densitometry of the BMP2K band was carried for each of the blots from
four separate experiments (untreated versus 2 lM: p , 0.05; and
untreated versus 100 lM: p, 0.01, n¼4). The inset blot is representative
of four separate experiments, where equal amounts of protein were
loaded in each lane.
DOI: 10.1371/journal.pmed.0020264.g005
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of arginine [21]. It is known that adding endogenous NO to
endothelial cells alters gene expression [22,23] and that
inhibitors of endogenous NO generation can alter expression
of speciﬁc genes, at least under conditions of endothelial cell
activation with cytokines. To determine whether the effects
we observed could be accounted for by inhibition of NOS, we
treated cells with a highly potent NOS inhibitor (L-NIO) and
with SDMA, an endogenous dimethylarginine that has no
effect on NOS but which can block arginine transport [10,16].
Neither SDMA nor L-NIO replicated the effects of ADMA on
gene expression. We have not undertaken a full GeneChip
analysis of responses to L-NIO, so we do not know how much
overlap there would be between the effects of L-NIO and
ADMA, but of those genes examined we saw a discordance
between responses to the two inhibitors. This raises the
intriguing possibility that some of the actions of ADMA may
be independent of effects of NO, possibly due to other
actions such as the ability of ADMA to increase superoxide
generation [24,25]. Other authors have reported differences
in efﬁcacy of ADMA in cell culture systems compared to
other NOS inhibitors that have more potent effects on
isolated NOS [26], and further studies will be required to
identify to what extent NO-independent effects contribute to
the overall action of ADMA. Interestingly, a NOS-independ-
ent effect of ADMA on angiotensin-converting enzyme has
recently been suggested [25]. NOS-independent effects of
ADMA may explain why, in some situations where ADMA
concentrations are raised, L-arginine does not restore normal
endothelial function [27] and why ADMA can exert effects,
even in the presence of high endogenous arginine concen-
trations.
Patterns of Gene Change
Mapping genes changed by ADMA to identify global
changes in biological processes [15], indicated that ADMA
treatment may have signiﬁcant effects on genes involved in
cell cycle regulation, cell proliferation, DNA repair, tran-
scriptional regulation, and metabolism. The full biological
signiﬁcance of the range of genes affected is not yet known,
but our data demonstrate the potential for elevated ADMA to
affect endothelial (and likely other cellular) function in
disease. In the present study, we focussed on two pathways of
potential importance—BMP pathways and PRMTs.
BMP Pathways and ADMA
Analysis of the U133A GeneChips revealed that BMP2K was
induced more than 2-fold in response to either 2 or 100 lM
ADMA. The increase in gene expression was mirrored by an
increase in BMP2K protein, and the effect was also seen in
our high-ADMA mouse model. By relaxing parameters (to
exclude false negatives) a search for other genes involved in
BMP signalling revealed that Smad5 and BMPR1A were also
amongst the transcripts increased by GeneChip analysis, and
these changes were conﬁrmed by Northern blotting. The
ﬁnding of changes in the BMP signalling pathway is
important since the ADMA/DDAH pathway seems to be
involved in animal models of pulmonary hypertension
[28,29], and mutations in the BMP receptor 2 (BMPR2) are
associated with familial pulmonary hypertension in humans
[30].
The changes in BMP pathways may also be important in
understanding some of the effects of renal failure. ADMA
accumulates in renal failure and fulﬁls many of the criteria of
a uraemic toxin [1,18]. In addition to effects on cardiovas-
Figure 6. Genes Involved in BMP Signalling are Altered by ADMA
Smad5 (A) and BMPR1A (B) are elevated in HCAEC following 24-h
treatment with ADMA (2 and 100 lM), as shown by Northern blotting
where mRNA was corrected for differences in b-actin mRNA expression
(*p , 0.05; ** p , 0.01, where n ¼ 4).
DOI: 10.1371/journal.pmed.0020264.g006
Figure 7. Involvement of ADMA-Affected Genes in the BMP Signalling
Pathway
Squares in yellow show genes that increased significantly on the
GeneChip, whilst squares in blue show genes decreased by ADMA
compared to untreated HCAEC, and ‘‘?’’ represents an unknown
mechanism of action.
DOI: 10.1371/journal.pmed.0020264.g007
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cular risk, ADMA may contribute to renal osteodystrophy, a
process in which BMPs have been implicated [31]. Indeed an
earlier study that showed that ADMA reduces osteoblast
differentiation and decreases osteocalcin expression [32]. The
present study conﬁrms osteocalcin as a gene downregulated
by ADMA, and since activation of BMP2K attenuates
osteocalcin expression and reduces osteoblast differentiation
[33], it is possible that the effects of ADMA on osteocalcin
may be secondary to induction of BMP2K (Figure 7).
Whatever the mechanisms, identiﬁcation of a link between
ADMA and BMP pathways may be relevant to the increased
vascular calciﬁcation seen in renal disease [31].
ADMA and Arginine Methylation
We observed that PRMT3 gene expression was elevated
following exposure to ADMA; this was conﬁrmed by Q-PCR,
and PRMT3 protein expression also increased. This is the ﬁrst
report that ADMA may alter the expression of enzymes
involved in its own synthesis. There are presently ﬁve known
PRMTs that asymmetrically methylate arginine residues and
two (PRMT5 and PRMT7) that symmetrically methylate
arginine residues. PRMT3 has a wide tissue distribution, is
expressed in highly vascular tissues, including heart and lung
[17], and expression may be increased by oxidised-LDL [34].
Our observations indicate that ADMA can induce a similar
increase in PRMT3 expression.
The roles of methylation of arginine residues in proteins
are not yet well deﬁned, but studies of PRMT3 in ﬁssion yeast
have shown that it associates with proteins involved in the
translational machinery and that the S2 ribosomal protein, a
component of the yeast 40S ribosome, is a speciﬁc substrate
for PRMT3 [35]. PRMT3 is the only PRMT known to interact
with the translational machinery, and it is interesting that we
have found several genes, including ribosomal proteins RpS11
and RpL27, involved in translational control, that were also
altered in response to ADMA treatment. Amongst the genes
changed greater than 1.7-fold in response to ADMA was
methionine adenosyltransferase II a, which catalyses the
production of S-adenosylmethionine, the methyl donor for
the PRMT reaction [36]. The role of ADMA in regulating
arginine methylation in protein deserves further study.
Summary
Increased circulating concentrations of ADMA have been
reported in cardiovascular and other disorders, and intra-
cellular concentrations may vary independently of circulating
levels. In the present study we have demonstrated that
relatively small changes in the concentration of ADMA affect
gene expression in endothelial cells. Identiﬁcation of path-
ways regulated by ADMA may aid our understanding of how
ADMA contributes to a wide range of pathologies. Two
pathways of speciﬁc interest have been identiﬁed—BMP
signalling and enzymes involved in arginine methylation. The
effects on BMP signalling may be particularly important in
renal disease and in the link between raised ADMA and
pulmonary hypertension.
Supporting Information
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The microarray data have been loaded into the EBI MIAMExpress
database (http://www.ebi.ac.uk/miamexpress/) and have been assigned
the accession number E-MEXP-377.
Table 5. Identification of Global Changes in Gene Expression in
HCAEC Following Treatment with 2 lM ADMA
Biological Process Number of Genes
Mapped to Process
EASE
Score
Metabolism 161 0.0252
Nucleobase, nucleoside, nucleotide,
and nucleic acid metabolism
77 0.0305
RNA splicing 8 0.0324
Antigen presentation,
endogenous antigen
3 0.0337
Antigen processing,
endogenous antigen via MHC class I
3 0.0337
Chromatin modification 6 0.0371
Antigen processing 4 0.0389
Regulation of transcription 50 0.0398
Protein metabolism 67 0.0407
Antigen presentation 4 0.0434
Cell organization and biogenesis 22 0.0441
Cell growth and/or maintenance 96 0.0462
Double-strand break repair 3 0.0493
Transcription 52 0.0506
Genes that changed by more than 1.7-fold in 2 lM treated compared to untreated HCAEC (465) were analysed by
DAVID-EASE [15] software (National Institutes of Health) to determine biological processes, based on gene ontology,
likely to have been affected by ADMA treatment.
MHC, major histocompatibility complex.
DOI: 10.1371/journal.pmed.0020264.t005
Table 6. Identification of Global Changes in Gene Expression in
HCAEC Following Treatment with 100 lM ADMA
Biological Process Number of Genes
Mapped to Process
EASE
Score
Cell growth and/or maintenance 183 0.0000126
Cytoplasm organization and biogenesis 29 0.000463
Cellular physiological process 199 0.000579
Antigen processing, endogenous
antigen via MHC class I
5 0.00103
Organelle organization and biogenesis 25 0.00141
Antigen processing 7 0.00142
Intracellular transport 35 0.0029
Cytoskeleton organization and biogenesis 20 0.00393
Cell cycle 45 0.00939
Antigen presentation 6 0.00996
Intracellular protein transport 27 0.00997
Antigen presentation,
endogenous antigen
4 0.0118
Cell proliferation 62 0.0138
Negative regulation of cell cycle 10 0.0141
Transport 86 0.0142
Positive regulation of cell proliferation 12 0.0157
Protein transport 27 0.0164
Regulation of cell cycle 28 0.0203
Cell organization and biogenesis 35 0.0272
Regulation of cell proliferation 20 0.0305
Pyrimidine nucleotide biosynthesis 4 0.0414
Vesicle-mediated transport 18 0.0487
Genes that changed by more than 1.7-fold in 100 lM treated compared to untreated HCAEC (765) were analysed by
DAVID-EASE [15] software (National Institutes of Health) to determine biological processes likely to have been
affected by ADMA treatment.
MHC, major histocompatibility complex.
DOI: 10.1371/journal.pmed.0020264.t006
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Patient Summary
Background Diseases of the circulation system are common and cause
many deaths. Medical conditions associated with damage to the blood
vessels include heart failure, high blood pressure, stroke, and kidney
failure. The lining of the blood vessels plays an active role in maintaining
their health. A substance called asymmetric dimethylarginine (ADMA) is
found naturally in the vessel lining, both in healthy people and in people
with vascular disease, but in the latter it is present at higher levels. Thus
raised ADMA may be a marker of vascular disease. This means it could be
used to help identify people with a circulation problem. However, it has
not been clear whether ADMA actually causes any damage, i.e., whether
it is more than just a marker.
What Did the Researchers Do and Find? The researchers are trying to
find out whether elevated ADMA levels can cause vascular disease. In
this study, they treated cells from blood vessel linings with levels of
ADMA equal to those found in people with vascular disease and
measured how gene activity changed in response. They found that a
number of genes were more active when the cells were exposed to the
elevated ADMA levels. Some of these were interesting because other
studies suggest that they might be involved in lung, heart, and kidney
disease.
What Do the Results Mean for Patients? This area of research is still at
an exploratory stage. Additional studies need to examine which function
(if any) the genes that respond to elevated ADMA levels play in vascular
disease. If they do play active roles, drugs that inhibit them might help to
prevent or treat vascular disease.
Where Can I Get More Information? For general information on
cardiovascular disease see information provided by the following
organisations.
The British Heart Foundation:
http://www.bhf.org.uk/hearthealth/index_home.asp?SecID¼1
The American Academy of Family Physicians:
http://familydoctor.org/292.xml
The National Heart, Lung, and Blood Institute:
http://www.nhlbi.nih.gov/health/public/heart/index.htm
New York Online Access to Health:
http://www.noah-health.org/en/blood/vascular/index.html
University College London:
http://www.ucl.ac.uk/medicine/clinical-pharmaco/research
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